γδ T cells

BIOLOGICAL4 trials

Sponsors

Fuda Cancer Hospital, Guangzhou, Beijing 302 Hospital

Conditions

Breast CancerHepatocellular CarcinomaLiver Cancer

Early Phase 1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Not yet recruitingNCT06364800

Beijing 302 HospitalHepatocellular Carcinoma

Start: 2024-04-26End: 2026-09-26Target: 18Updated: 2024-04-15

Phase 1

Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer

CompletedNCT02425735

Fuda Cancer Hospital, GuangzhouLiver Cancer

Start: 2015-04-30End: 2016-06-30Updated: 2016-07-19

Safety and Efficiency of γδ T Cell Against Breast Cancer

CompletedNCT03183206

Fuda Cancer Hospital, GuangzhouBreast Cancer

Start: 2017-06-15End: 2019-06-15Updated: 2020-07-13

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Not yet recruitingNCT06364787

Beijing 302 HospitalHepatocellular Carcinoma

Start: 2024-04-26End: 2026-09-26Target: 18Updated: 2024-04-15

Related Papers

Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.

2019-02-08105 citations